
ID: uzexd9h1,
Text: drug repurposing prediction for covid using probabilistic networks and crowdsourced curation severe acute respiratory syndrome coronavirus two sars cov the virus responsible for the coronavirus disease covid pandemic represents an unprecedented global health challenge consequently a large amount of research into the disease pathogenesis and potential treatments has been carried out in a short time frame however developing novel drugs is a costly and lengthy process and is unlikely to deliver a timely treatment for the pandemic drug repurposing by contrast provides an attractive alternative as existing drugs have already undergone many of the regulatory requirements in this work we used a combination of network algorithms and human curation to search integrated knowledge graphs identifying drug repurposing opportunities for covid we demonstrate the value of this approach reporting on eight potential repurposing opportunities identified and discuss how this approach could be incorporated into future studies

ID: r4snyxr9,
Text: repurposing host based therapeutics to control coronavirus and influenza virus the development of highly effective antiviral agents has been a major objective in virology and pharmaceutics drug repositioning has emerged as a cost effective and time efficient alternative approach to traditional drug discovery and development this new shift focuses on the repurposing of clinically approved drugs and promising preclinical drug candidates for the therapeutic development of host based antiviral agents to control diseases caused by coronavirus and influenza virus host based antiviral agents target host cellular machineries essential for viral infections or innate immune responses to interfere with viral pathogenesis this review discusses current knowledge prospective applications and challenges in the repurposing of clinically approved and preclinically studied drugs for newly indicated antiviral therapeutics

ID: l76lspvx,
Text: coronavirus puts drug repurposing on the fast track

ID: 7r6j9dgo,
Text: coronavirus puts drug repurposing on the fast track

ID: hcj8fylw,
Text: perspectives for repurposing drugs for the coronavirus disease the newly emerged novel coronavirus cov named as severe acute respiratory syndrome cov sars cov like sars cov now sars cov and middle east respiratory syndrome cov mers cov has been associated with high infection rates with over deaths in the absence of approved marketed drugs against coronaviruses the treatment and management of this novel cov disease covid worldwide is a challenge drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery direct virus targeted antiviral agents target specific nucleic acid or proteins of the virus while host based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection both the approaches necessarily interfere with viral pathogenesis here we summarize the present status of both virus based and host based drug repurposing perspectives for coronaviruses in general and the sars cov in particular

ID: 2rlld533,
Text: a brief overview of current drug repurposing approaches for covid management this brief overview is intended to shed light on the current drug repositioning also called drug repurposing in the therapeutics of the novel coronavirus disease which emerged in covid in this sense the repositioning drugs for new indications can offer a better risk versus reward trade off when compared to other drug development strategies given that it makes use of drugs whose safety profile are already understood nonetheless this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it

ID: q6bpic9m,
Text: current status of covid therapies and drug repositioning applications the rapid and global spread of a new human coronavirus sars cov has produced an immediate urgency to discover promising targets for the treatment of covid drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications here we review current information concerning the global health issue of covid including promising approved drugs and ongoing clinical trials for prospective treatment options in addition we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against sars cov

ID: qmlmiqtv,
Text: combating devastating covid by drug repurposing despite advances in drug discovery viral infections remain a major challenge for scientists across the globe the recent pandemic of covid coronavirus disease caused by a viral infection with sars cov severe acute respiratory syndrome coronavirus has created a disastrous situation all over the world as no drugs are available to treat this life threatening disease and the mortality rate due to covid is high there is an utmost need to attempt to treat the infection using drug repurposing some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they have been found to be effective in some countries to treat covid patients off label investigational this article emphasises possible drug candidates in the treatment of covid most of these drugs were found to be effective in in vitro studies there is a need to re assess in vitro data and to carry out randomised clinical trials further investigations of these drugs are recommended on a priority basis

ID: 1t4ykc01,
Text: current status of covid therapies and drug repositioning applications summary the rapid and global spread of a new human coronavirus sars cov has produced an immediate urgency to discover promising targets for treatment of covid drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications here we review current information concerning the global health issue of covid including promising approved drugs and ongoing clinical trials for prospective treatment options in addition we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against sars cov

ID: s953j62y,
Text: computational studies of drug repurposing and synergism of lopinavir oseltamivir and ritonavir binding with sars cov protease against covid a novel coronavirus sars cov has caused a major outbreak in humans all over the world and it is the latest pandemic in the series of other infectious diseases the concept of drug repurposing has been used successfully for many years for known diseases considering the emergency and urgency drug repurposing concept is being explored for coronavirus disease covid as well recently the combination of three known drugs lopinavir oseltamivir and ritonavir has been proposed to control the virulence to a great extent in covid affected patients within hours hence we tried to understand the effect of synergism of these drugs against the sars cov protease using sequential docking studies as a result combination of three drugs showed a better binding energy than that of individual drugs further the complex was subjected to molecular dynamics simulations to get insights into the stability of the complex considering the simultaneous interactions between three drugs and the protein the protein complexed with three drugs remained stable during the simulations hence these drugs can be explored further for drug repurposing against the successful inhibition of covid

ID: b4mdiont,
Text: network based drug repurposing for human coronavirus human coronaviruses hcovs including severe acute respiratory syndrome coronavirus sars cov middle east respiratory syndrome coronavirus mers cov and novel coronavirus ncov lead global epidemics with high morbidity and mortality however there are currently no effective drugs targeting ncov drug repurposing represented as an effective drug discovery strategy from existing drugs could shorten the time and reduce the cost compared to de novo drug discovery in this study we present an integrative antiviral drug repurposing methodology implementing a systems pharmacology based network medicine platform quantifying the interplay between the hcov host interactome and drug targets in the human protein protein interaction network phylogenetic analyses of hcov whole genomes reveal that ncov has the highest nucleotide sequence identity with sars cov among the six other known pathogenic hcovs specifically the envelope and nucleocapsid proteins of ncov are two evolutionarily conserved regions having the sequence identities of and respectively compared to sars cov using network proximity analyses of drug targets and known hcov host interactions in the human protein protein interactome we computationally identified putative repurposable drugs for the potential prevention and treatment of hcovs in addition we prioritized potential anti hcov repurposable drugs including melatonin mercaptopurine and sirolimus that were further validated by enrichment analyses of drug gene signatures and hcov induced transcriptomics data in human cell lines finally we showcased three potential drug combinations including sirolimus plus dactinomycin mercaptopurine plus melatonin and toremifene plus emodin captured by the complementary exposure pattern the targets of the drugs both hit the hcov host subnetwork but target separate neighborhoods in the human protein protein interactome network in summary this study offers powerful network based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations toward future clinical trials for hcovs

ID: 4yuw7jo3,
Text: network based drug repurposing for novel coronavirus ncov sars cov human coronaviruses hcovs including severe acute respiratory syndrome coronavirus sars cov and novel coronavirus ncov also known as sars cov lead global epidemics with high morbidity and mortality however there are currently no effective drugs targeting ncov sars cov drug repurposing representing as an effective drug discovery strategy from existing drugs could shorten the time and reduce the cost compared to de novo drug discovery in this study we present an integrative antiviral drug repurposing methodology implementing a systems pharmacology based network medicine platform quantifying the interplay between the hcov host interactome and drug targets in the human protein protein interaction network phylogenetic analyses of hcov whole genomes reveal that ncov sars cov shares the highest nucleotide sequence identity with sars cov specifically the envelope and nucleocapsid proteins of ncov sars cov are two evolutionarily conserved regions having the sequence identities of and respectively compared to sars cov using network proximity analyses of drug targets and hcov host interactions in the human interactome we prioritize potential anti hcov repurposable drugs e g melatonin mercaptopurine and sirolimus that are further validated by enrichment analyses of drug gene signatures and hcov induced transcriptomics data in human cell lines we further identify three potential drug combinations e g sirolimus plus dactinomycin mercaptopurine plus melatonin and toremifene plus emodin captured by the complementary exposure pattern the targets of the drugs both hit the hcov host subnetwork but target separate neighborhoods in the human interactome network in summary this study offers powerful network based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting ncov sars cov

ID: qnccsstb,
Text: host transcriptome guided drug repurposing for covid treatment a meta analysis based approach background coronavirus disease covid caused by severe acute respiratory syndrome coronavirus sars cov has been declared a pandemic by the world health organization and the identification of effective therapeutic strategy is a need of the hour to combat sars cov infection in this scenario the drug repurposing approach is widely used for the rapid identification of potential drugs against sars cov considering viral and host factors methods we adopted a host transcriptome based drug repurposing strategy utilizing the publicly available high throughput gene expression data on sars cov and other respiratory infection viruses based on the consistency in expression status of host factors in different cell types and previous evidence reported in the literature pro viral factors of sars cov identified and subject to drug repurposing analysis based on drugbank and connectivity map cmap using the web tool clue results the upregulated pro viral factors such as tymp ptgs c s cfb ifi xaf cxcl and cxcl were identified in early infection models of sars cov by further analysis of the drug perturbed expression profiles in the connectivity map drugs that can reverse the expression of pro viral factors were identified and importantly twelve of them reported to have anti viral activity the direct inhibition of the ptgs gene product can be considered as another therapeutic strategy for sars cov infection and could suggest six approved ptgs inhibitor drugs for the treatment of covid the computational study could propose candidate repurposable drugs against covid and further experimental studies are required for validation

ID: xui8cfzv,
Text: repurposing cefuroxime for treatment of covid a scoping review of in silico studies severe acute respiratory syndrome coronavirus sars cov the causative agent of coronavirus disease covid is a novel human coronavirus that is responsible for about deaths worldwide to date there is no confirmed treatment or vaccine prevention strategy against covid due to the urgent need for effective treatment drug repurposing is regarded as the immediate option potential drugs can often be identified via in silico drug screening experiments consequently there has been an explosion of in silico experiments to find drug candidates or investigate anecdotal claims one drug with several anecdotal accounts of benefit is cefuroxime the aim of this study was to identify and summarize in silico evidence for possible activity of cefuroxime against sars cov to this end we performed a scoping review of literature of in silico drug repurposing experiments for sars cov using prisma scr we searched medline embase scopus web of knowledge and google scholar for original studies published between st feb and th may that screened drug libraries and identified cefuroxime as a top ranked potential inhibitor drug against sars cov proteins six studies were identified these studies reported cefuroxime as a potential inhibitor of key sars cov proteins main protease rna dependent rna polymerase and ace spike complex we provided a summary of the methodology and findings of the identified studies our scoping review identified significant in silico evidence that cefuroxime may be a potential multi target inhibitor of sars cov further in vitro and in vivo studies are required to evaluate the potential of cefuroxime for covid communicated by ramaswamy h sarma

ID: kq3qnhap,
Text: mass drug administration and worms experience in africa envisage repurposing ivermectin for sars cov mass drug administration and worms experience in africa envisage repurposing ivermectin for sars cov

ID: ip4wpdib,
Text: overcoming cancer therapeutic bottleneck by drug repurposing ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing the development of old drugs for new therapeutic purposes this strategy with a cost effective way offers a rare opportunity for the treatment of human neoplastic disease facilitating rapid clinical translation with an increased understanding of the hallmarks of cancer and the development of various data driven approaches drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target defined antineoplastic compounds the treasure trove of non oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer indeed different from targeted drugs these old generic drugs usually used in a multi target strategy may bring benefit to patients in this review aiming to demonstrate the full potential of drug repurposing we present various promising repurposed non oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono or drug combination therapy we also summarize approaches used for drug repurposing and discuss the main barriers to its uptake

ID: d9v8qo7v,
Text: drug repurposing a better approach for infectious disease drug discovery the advent of publically available databases containing system wide phenotypic data of the host response to both drugs and pathogens in conjunction with bioinformatics and computational methods now allows for in silico predictions of fda approved drugs as treatments against infection diseases this systems biology approach captures the complexity of both the pathogen and drug host response in the form of expression patterns or molecular interaction networks without having to understand the underlying mechanisms of action these drug repurposing techniques have been successful in identifying new drug candidates for several types of cancers and were recently use to identify potential therapeutics against influenza the newly discovered middle eastern respiratory syndrome coronavirus and several parasitic diseases these new approaches have the potential to significantly reduce both the time and cost for infectious diseases drug discovery

ID: aqge7xuu,
Text: repurposing cefuroxime for treatment of covid a scoping review of in silico studies severe acute respiratory syndrome coronavirus sars cov the causative agent of coronavirus disease covid is a novel human coronavirus that is responsible for about deaths worldwide to date there is no confirmed treatment or vaccine prevention strategy against covid due to the urgent need for effective treatment drug repurposing is regarded as the immediate option potential drugs can often be identified via in silico drug screening experiments consequently there has been an explosion of in silico experiments to find drug candidates or investigate anecdotal claims one drug with several anecdotal accounts of benefit is cefuroxime the aim of this study was to identify and summarize in silico evidence for possible activity of cefuroxime against sars cov to this end we performed a scoping review of literature of in silico drug repurposing experiments for sars cov using prisma scr we searched medline embase scopus web of knowledge and google scholar for original studies published between st feb and th may that screened drug libraries and identified cefuroxime as a top ranked potential inhibitor drug against sars cov proteins six studies were identified these studies reported cefuroxime as a potential inhibitor of key sars cov proteins main protease rna dependent rna polymerase and ace spike complex we provided a summary of the methodology and findings of the identified studies our scoping review identified significant in silico evidence that cefuroxime may be a potential multi target inhibitor of sars cov further in vitro and in vivo studies are required to evaluate the potential of cefuroxime for covid communicated by ramaswamy h sarma

ID: fdrrbr6a,
Text: repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars cov repurposing clinically available drugs to treat the new coronavirus disease covid is an urgent need in these early stages of the sars cov pandemic when very few treatment options are available the iminosugar miglustat is a well characterized drug for the treatment of rare genetic lysosome storage diseases such as gaucher and niemann pick type c and has also been described to be active against a variety of enveloped viruses the activity of miglustat is here demonstrated for sars cov at concentrations achievable in the plasma by current clinical regimens without cytotoxicity the drug acts at the post entry level and leads to a marked decrease of viral proteins and release of infectious virus the mechanism resides in the inhibitory activity towards α glucosidases that are involved in early stages of glycoprotein n linked oligosaccharide processing in the endoplasmic reticulum leading to a marked decrease of the viral spike protein the wealth of available data on the clinical use of miglustat for the treatment of lysosomal storage disorders and the antiviral properties against sars cov make it an ideal candidate for drug repurposing

ID: 9idkf0i9,
Text: an update on therapeutic repurposing strategies for covid the severe acute respiratory syndrome coronavirus well known as covid has become the current health distress to the entire world in the pandemic scenario the research on the rapid development of new drug molecules is highly risky and tedious process the current covid emergency demands an urgent development of possible strategies to protect people at high risk of infection and hence the drug repurposing became an emerging approach to fight covid this review summarizes an update on various therapeutic strategies with special attention on repurposing of drugs to fight against sars cov worldwide the investigation of existing drugs for new therapeutic purposes is one line of scientific research followed to develop safe and effective covid treatments broad spectrum antiviral agents bsaas that have been believed to be safe through testing on early phase clinical trials have been hyped as good drug repurposing candidates broad spectrum antiviral drugs such as ribavirin umifenovir were advised for covid treatment some antibiotics may be repurposed as covid treatments such as teicoplanin oritavancin dalbavancin monensin and azithromycin ivermectin an antiparasitic is recently repurposed hydroxychloroquine and chloroquine having immunomodulating effect on humans have been shown to have antiviral activity at starting and post entry stages of the sars cov infection there is a need for global health emergency to call for a courageous global response at the political and governmental levels therefore the regulatory agencies must act swiftly to lessen any financial obstacles involving private companies and update guidelines for drug licenses by repurposing if necessary
